ScreenHER

Developing a high-sensitivity, point-of-care diagnostic platform for cervical precancer and cancer screening.

Cover Block

PUBLIC
Name ScreenHER
Tagline Developing a high-sensitivity, point-of-care diagnostic platform for cervical precancer and cancer screening.
Headquarters Cincinnati, United States
Stage Pre-Seed
Business Model Hardware + Software
Industry Healthtech
Technology Biotech / Life Sciences
Geography North America
Growth Profile Venture Scale

Links

PUBLIC

Executive Summary

PUBLIC ScreenHER is an early-stage healthtech startup developing a point-of-care diagnostic platform for cervical precancer and cancer screening, a bet that deserves investor attention for its focus on a critical, underserved area of women's health with significant global access gaps [PERPLEXITY SONAR PRO BRIEF]. The company's founding story is not publicly documented, and its founders remain unnamed across its corporate site and LinkedIn profile, a notable absence that limits any assessment of team pedigree [PERPLEXITY SONAR PRO BRIEF]. Its core product is described as a high-sensitivity, rapid-format test designed for use in clinical or community health settings, aiming to improve early detection rather than replace established lab-based methods [PERPLEXITY SONAR PRO BRIEF]. This positioning suggests a wedge strategy targeting low-resource or under-screened populations, but the company has not disclosed technical details on assay chemistry, device form factor, or regulatory pathway. No funding rounds, investors, or a defined business model are visible in the public record, indicating the company is likely in a pre-seed, stealth phase of development. Over the next 12-18 months, the key milestones to watch will be the emergence of named founders with relevant diagnostics experience, the announcement of initial grant or seed funding, and any public steps toward clinical validation or pilot partnerships. Data Accuracy: YELLOW -- Product claims are based on the company's own description; team and funding details are absent from public sources.

Taxonomy Snapshot

Axis Value
Stage Pre-Seed
Business Model Hardware + Software
Industry / Vertical Healthtech
Technology Type Biotech / Life Sciences
Geography North America
Growth Profile Venture Scale

Company Overview

PUBLIC ScreenHER is a very early-stage women's health diagnostics company based in Cincinnati, Ohio, focused on point-of-care cervical cancer screening. The company's public presence is minimal, with its founding story, leadership, and corporate milestones not yet disclosed in any mainstream press or regulatory filings [PERPLEXITY SONAR PRO BRIEF]. Its primary description, sourced from its own materials, is that of a developer of a high-sensitivity, point-of-care diagnostic platform for cervical precancer and cancer [PERPLEXITY SONAR PRO BRIEF].

No founding date, named founders, or key operational milestones such as regulatory submissions, pilot study initiations, or grant awards are publicly available. The company's LinkedIn profile confirms its Cincinnati location but does not list an executive team [PERPLEXITY SONAR PRO BRIEF]. This lack of public detail places ScreenHER in a pre-operational or stealth development phase, with its chronology defined more by its current positioning than by a track record of verifiable events.

Data Accuracy: YELLOW -- Company claims are sourced from its own site and LinkedIn; no independent public corroboration for founding details or milestones exists.

Product and Technology

MIXED ScreenHER's public product definition is a high-level promise, not a detailed specification. The company describes its work as developing a "high-sensitivity, point-of-care diagnostic platform" designed to identify cervical precancerous and cancer signals in a simple, rapid format [PERPLEXITY SONAR PRO BRIEF]. This positioning frames the product as a tool for clinical or near-patient settings, such as an OB-GYN office or a community health clinic, with an implied wedge around improving access and speed for under-screened populations.

Beyond this mission statement, the public record contains no technical details. The company has not disclosed the assay chemistry, the form factor of the diagnostic device, or the specific biomarkers targeted. There is also no public information regarding regulatory strategy, such as whether the platform is being developed for CLIA-waived status or for a more complex FDA pathway. The absence of named pilot sites or clinical partners further limits any assessment of the technology's current stage of development.

Data Accuracy: YELLOW -- Product claims are sourced solely from the company's own description; no independent technical validation or detailed specifications are available.

Market Research

PUBLIC

Cervical cancer remains a preventable disease where early detection is critical, yet screening access is unevenly distributed, creating a persistent gap that new point-of-care technologies aim to address.

The total addressable market for cervical cancer screening is substantial, anchored by the global population of women of screening age. According to the World Health Organization, cervical cancer is the fourth most common cancer among women globally, with an estimated 604,000 new cases and 342,000 deaths in 2020 [WHO, 2023]. The WHO's global strategy to accelerate the elimination of cervical cancer sets targets for 70% of women to be screened by 2030, representing a significant push for expanded screening coverage. In the United States, the Centers for Disease Control and Prevention reports that over 14,000 new cases of cervical cancer are diagnosed each year [CDC, 2023]. The direct market for screening tests includes established laboratory-based cytology (Pap smears) and high-risk human papillomavirus (HPV) DNA testing, which collectively represent a multi-billion dollar global diagnostics segment. For context, the global cervical cancer diagnostics market was valued at $6.8 billion in 2022 and is projected to grow at a compound annual rate of approximately 5% through 2030, according to a third-party industry report (analogous market, source) [Grand View Research, 2023].

Demand for new screening solutions is driven by several converging tailwinds. Persistent screening disparities in low-resource, rural, and underserved communities create a clear wedge for decentralized, rapid testing. Public health initiatives, such as the WHO's elimination campaign and the U.S. National Cancer Institute's Cancer Moonshot, are increasing funding and policy focus on closing screening gaps. There is also a growing clinical preference for primary HPV testing over cytology due to its higher sensitivity for detecting precancerous lesions, a shift that is reshaping the testing landscape and creating opportunities for new assay formats. Furthermore, the broader trend toward patient-centric care and value-based healthcare models incentivizes technologies that can deliver results within a single clinical visit, reducing loss to follow-up, which is a major barrier to effective treatment.

Key adjacent and substitute markets influence the commercial pathway. The market for HPV vaccination, while preventative rather than diagnostic, impacts long-term screening volumes and protocols. The broader point-of-care diagnostics market, valued at over $40 billion globally, demonstrates the commercial viability and adoption pathways for decentralized testing platforms across infectious diseases, cardiometabolic conditions, and coagulation monitoring [Kalorama Information, 2023]. ScreenHER's platform would also compete indirectly with telemedicine and self-sampling initiatives, which represent alternative approaches to improving access by removing geographic or clinic-based barriers.

Regulatory and macro forces present both a gating mechanism and a potential catalyst. In the United States, any diagnostic test claiming to detect cervical precancer or cancer requires pre-market review by the Food and Drug Administration, a process that defines the timeline to commercialization and the clinical evidence required. Reimbursement from public payers like the Centers for Medicare & Medicaid Services and private insurers is contingent on demonstrating clinical utility and cost-effectiveness, often through large-scale clinical trials. Globally, alignment with the WHO's prequalification of in vitro diagnostics is essential for adoption in low- and middle-income country public health programs, which represent a key target population for improving access.

Metric Value
Global Cervical Cancer Diagnostics Market (2022) 6.8 $B
Projected CAGR (2023-2030) 5 %
Global Point-of-Care Diagnostics Market 40 $B

The sizing figures illustrate the established scale of the core diagnostics market ScreenHER intends to enter, while the larger adjacent point-of-care market suggests a proven commercial pathway for decentralized testing models. The single-digit growth projection for the core market indicates maturity, underscoring that a new entrant's growth would depend on capturing share from incumbents or expanding the screened population in underserved segments.

Data Accuracy: YELLOW -- Market sizing figures are drawn from third-party industry reports and public health agency statistics, which provide a reliable analog. Specific demand drivers and regulatory pathways are well-documented public knowledge. No company-specific market claims are available for verification.

Competitive Landscape

MIXED ScreenHER’s competitive position is defined by its ambition to insert a rapid, point-of-care device into a cervical cancer screening workflow historically dominated by centralized laboratory services.

Given the absence of named competitors in the structured research, a direct comparison table cannot be rendered. The analysis proceeds on the broader competitive map inferred from the company's stated focus.

The competitive environment for cervical cancer diagnostics is segmented by technology and setting. Incumbent laboratory-based cytology (Pap smears) and molecular HPV tests, offered by giants like Roche and Hologic, represent the entrenched standard of care. These are high-sensitivity but require complex logistics, trained cytotechnologists, and days to weeks for results, creating the access gap ScreenHER aims to address. The primary challengers are other point-of-care and self-collection startups, such as Visby Medical (portable PCR) and Daye (at-home vaginal health testing), though none are confirmed to be targeting the same specific cervical precancer signal with a rapid, clinic-based format. Adjacent substitutes include emerging AI-powered digital cytology platforms, which aim to improve the accuracy of traditional Pap smear analysis rather than change the collection-to-result timeline.

ScreenHER’s proposed edge rests on the combination of high sensitivity and point-of-care speed, a wedge into low-resource and under-screened populations where lab infrastructure is a barrier. This edge is perishable, however, as it is predicated on unproven technical execution and regulatory clearance. The company’s current lack of public detail on assay chemistry or device form factor makes it impossible to assess the durability of any technical moat. A defensible position would require proprietary biomarkers, a patented detection method, or exclusive partnerships with global health procurement bodies, none of which are yet in evidence.

The company’s most significant exposure is to the regulatory and commercial scale of established diagnostics firms. A competitor like Roche could use its existing global distribution network for HPV tests to deploy a rapid, clinic-based variant, potentially overwhelming a nascent entrant. Furthermore, ScreenHER’s focus on point-of-care suggests it may lack the clinical data and billing infrastructure to compete effectively in well-resourced, reimbursement-driven markets like the United States, ceding that segment to incumbents.

The most plausible 18-month scenario hinges on validation. If ScreenHER can publicly disclose a completed pilot study with a named health system or NGO, demonstrating clinical accuracy and user acceptance, it would establish a beachhead and likely attract grant or venture funding to scale. The winner in such a scenario would be any entity that first secures a World Health Organization prequalification for use in low-and-middle-income countries. Conversely, if the technical development stalls or a larger competitor announces a comparable point-of-care HPV test, ScreenHER would lose its first-mover narrative and face severe challenges in securing the capital needed for the lengthy FDA or CE Mark regulatory pathways.

Data Accuracy: YELLOW -- Competitive map is inferred from company positioning and general market knowledge; no direct competitors are named in available sources.

Opportunity

PUBLIC ScreenHER's opportunity rests on a single, high-stakes outcome: becoming the standard of care for cervical cancer screening in the majority of the world's clinical settings where access to advanced laboratory infrastructure is limited or non-existent.

The headline opportunity is the creation of a new global screening paradigm. The company's stated focus on a high-sensitivity, point-of-care platform for cervical precancer and cancer signals targets the core failure of the existing system, which is its reliance on centralized laboratory infrastructure and complex patient follow-up [PERPLEXITY SONAR PRO BRIEF]. If ScreenHER's technology can deliver lab-grade accuracy in a rapid, clinic-room format, it could shift the screening workflow from a multi-visit, weeks-long process to a single-visit diagnosis and potential treatment pathway. This outcome is reachable not because of ScreenHER's proven execution, but because the clinical need is so acute and well-documented; the World Health Organization has a global strategy to eliminate cervical cancer, with a key pillar being the scale-up of screening and treatment. A successful point-of-care tool would be a direct enabler of that goal, creating a multi-billion dollar market for the company that defines it.

Growth would likely follow one of several distinct paths, each with a different initial wedge and scaling catalyst.

Scenario What happens Catalyst Why it's plausible
Public Health Wedge ScreenHER becomes the tool of choice for national screening programs in low- and middle-income countries, funded by global health initiatives. A partnership with a major NGO (e.g., PEPFAR, Gates Foundation) or a government tender for a national screening rollout. The company's messaging explicitly targets improving access in low-resource or under-screened populations, aligning with the procurement priorities of major global health funders [PERPLEXITY SONAR PRO BRIEF].
US Community Health Expansion The platform is adopted by Federally Qualified Health Centers (FQHCs) and rural clinics in the US, addressing domestic care deserts. Securing a CPT reimbursement code for the point-of-care test or a pilot with a large FQHC network. The US has significant geographic and socioeconomic disparities in cervical cancer screening rates; a simple, rapid test that reduces loss to follow-up would address a documented pain point for safety-net providers.
OB-GYN Office Standard The test is integrated into routine well-woman visits in private practice, replacing the traditional Pap smear or HPV test sample that is sent out. Publication of a pivotal clinical trial demonstrating non-inferiority to standard lab tests and securing FDA clearance. Point-of-care convenience and immediate results are powerful value propositions in a fee-for-service environment, and adoption by a single large practice group could create a reference case for others.

Compounding success in this market would look like a classic diagnostic flywheel, though evidence of it spinning for ScreenHER is not yet public. Initial deployments in any of the above scenarios would generate real-world performance data across diverse patient populations. This dataset, if proprietary, could be used to refine the assay's algorithm, improve its sensitivity and specificity, and potentially expand its indications (e.g., detecting other HPV-related cancers). Superior data could then be submitted to regulatory bodies to support expanded claims, making the product more valuable and defensible. Furthermore, embedding the test into a health system's or country's standard workflow creates significant switching costs; retraining staff and changing clinical protocols represents a meaningful barrier to competitive displacement once ScreenHER is established.

To size the win, investors can look to the trajectory of other companies that successfully created new point-of-care diagnostic categories. Cepheid, now part of Danaher, built a multi-billion dollar business around its GeneXpert molecular diagnostic systems, which brought complex lab testing to near-patient settings. While a direct valuation comparable is premature, the economic model is instructive. If ScreenHER captured even a single-digit percentage of the estimated 100+ million cervical screening tests performed annually in its target markets, at a price point likely ranging from tens to hundreds of dollars per test, it would represent a revenue base sufficient to support a venture-scale outcome (scenario, not a forecast). The ultimate prize is not just the test consumables, but the potential platform value of the installed base for future assay menu expansion.

Data Accuracy: YELLOW -- The opportunity analysis is based on the company's stated mission and the well-documented structural gaps in global cervical cancer screening. The specific growth scenarios and compounding effects are plausible extrapolations, but not yet supported by public evidence of ScreenHER's execution against them.

Sources

PUBLIC

  1. [PERPLEXITY SONAR PRO BRIEF] ScreenHER Company Description | https://www.perplexity.ai

  2. [WHO, 2023] WHO Global Strategy to Accelerate the Elimination of Cervical Cancer | https://www.who.int/publications/i/item/9789240014107

  3. [CDC, 2023] Cervical Cancer Statistics | https://www.cdc.gov/cancer/cervical/statistics/index.htm

  4. [Grand View Research, 2023] Cervical Cancer Diagnostics Market Size Report | https://www.grandviewresearch.com/industry-analysis/cervical-cancer-diagnostics-market

  5. [Kalorama Information, 2023] Point of Care Diagnostics Market | https://kaloramainformation.com/product/point-of-care-diagnostics-market/

Articles about ScreenHER

View on Startuply.vc